Anti-VEGF antibody enhances the antitumor effect of CD40

International Journal of Cancer

Volumn 135, Issue 8, 2014, Pages 1983-1988

  Selvaraj, Sathishkumar ^a   Raundhal, Mahesh ^a   Patidar, Ashok ^a   Saha, Bhaskar ^a  

^a NATIONAL CENTRE FOR CELL SCIENCE   (India)

Author keywords

antitumor immunity; CD40; cytotoxic T cells; VEGF

Indexed keywords

ANGIOPOIETIN 1; ANGIOPOIETIN 2; ANGIOPOIETIN RECEPTOR; CD40 ANTIGEN; GAMMA INTERFERON; IMMUNOGLOBULIN G1; IMMUNOGLOBULIN G2A; IMMUNOGLOBULIN M; INTERLEUKIN 10; VASCULOTROPIN ANTIBODY; VASCULOTROPIN B; VASCULOTROPIN RECEPTOR 1; VASCULOTROPIN RECEPTOR 2;

ANIMAL MODEL; ANTIANGIOGENIC ACTIVITY; ANTINEOPLASTIC ACTIVITY; ARTICLE; B LYMPHOCYTE ACTIVATION; CANCER SURVIVAL; CELL PROLIFERATION; CONTROLLED STUDY; CYTOTOXIC T LYMPHOCYTE; DRUG RESPONSE; ENZYME LINKED IMMUNOSORBENT ASSAY; IMMUNE RESPONSE; IMMUNOMODULATION; INTERFERON PRODUCTION; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROSTATE CANCER; PROSTATE CANCER CELL LINE; PROTEIN EXPRESSION; REAL TIME POLYMERASE CHAIN REACTION; TUMOR GROWTH; TUMOR MICROENVIRONMENT; TUMOR REGRESSION; TUMOR VOLUME; WESTERN BLOTTING;

ANTITUMOR IMMUNITY; CD40; CYTOTOXIC T CELLS; VEGF;

ANIMALS; ANTIBODIES; ANTIGENS, CD40; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CELL LINE, TUMOR; CELL PROLIFERATION; HUMANS; INTERFERON-GAMMA; MICE; MICE, INBRED C57BL; T-LYMPHOCYTES; TUMOR BURDEN; TUMOR MICROENVIRONMENT; VASCULAR ENDOTHELIAL GROWTH FACTOR A; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84905741097     PISSN: 00207136     EISSN: 10970215     Source Type: Journal    
DOI: 10.1002/ijc.28833     Document Type: Article

References (20)

1. Pardoll D,. Does the immune system see tumors as foreign or self? Annu Rev Immunol 2003; 21: 807-39.
2. Rabinovich GA, Gabrilovich D, Sotomayor EM,. Immunosuppressive strategies that are mediated by tumor cells. Annu Rev Immunol 2007; 25: 267-96.
3. Murugaiyan G, Agrawal R, Mishra GC, et al. Functional dichotomy in CD40 reciprocally regulates effector T cell functions. J Immunol 2006; 177: 6642-9.
4. Murugaiyan G, Agrawal R, Mishra GC, et al. Differential CD40/CD40L expression results in counteracting antitumor immune responses. J Immunol 2007; 178: 2047-55.
5. Schoenberger SP, Toes RE, van der Voort EI, et al. T-cell help for cytotoxic T lymphocytes is mediated by CD40-CD40L interactions. Nature 1998; 393: 480-3.
6. - tumors through induction of strong systemic cytotoxic T lymphocyte immunity. Proc Natl Acad Sci USA 2002; 99: 5561-6.
7. Karmann K, Hughes CW, Schechner J, et al. CD40 on human endothelial cells: Inducibility by cytokines and functional regulation of adhesion molecule expression. Proc Natl Acad Sci USA 1995; 92: 4342-6.
8. Murugaiyan G, Martin S, Saha B,. CD40-induced countercurrent conduits for tumor escape or elimination? Trends Immunol 2007; 28: 467-73.
9. Melter M, Reinders ME, Sho M, et al. Ligation of CD40 induces the expression of vascular endothelial growth factor by endothelial cells and monocytes and promotes angiogenesis in vivo. Blood 2000; 96: 3801-8.
10. Reinders ME, Sho M, Robertson SW, et al. Proangiogenic function of CD40 ligand-CD40 interactions. J Immunol 2003; 171: 1534-41.
11. Kim KJ, Li B, Winer J, et al. Inhibition of vascular endothelial growth factor-induced angiogenesis suppresses tumor growth in vivo. Nature 1993; 362: 841-4.
12. Murugaiyan G, Martin S, Saha B,. Levels of CD40 expression on dendritic cells dictate tumor growth or regression. Clin Exp Immunol 2007; 149: 194-202.
13. Srivastava N, Sudan R, Saha B,. CD40-modulated dual-specificity phosphatases MAPK phosphatase (MKP)-1 and MKP-3 reciprocally regulate Leishmania major Infection. J Immunol 2011; 186: 5863-72.
14. Sathawane D, Kharat RS, Halder S, et al. Monocyte CD40 expression in head and neck squamous cell carcinoma (HNSCC). Hum Immunol 2013; 74: 1-5.
15. Ferrara N, Gerber HP, LeCouter J,. The biology of VEGF and its receptors. Nat Med 2003; 9: 669-76.
16. Waltenberger J, Claesson-Welsh L, Siegbahn A, et al. Different signal transduction properties of KDR and Flt1, two receptors for vascular endothelial growth factor. J Biol Chem 1994; 269: 26988-95.
17. Huang K, Andersson C, Roomans GM, et al. Signaling properties of VEGF receptor-1 and -2 homo- and heterodimers. Int J Biochem Cell Biol 2001; 33: 315-24.
18. Falcon BL, Hashizume H, Koumoutsakos P, et al. Contrasting actions of selective inhibitors of angiopoietin-1 and angiopoietin-2 on the normalization of tumor blood vessels. Am J Pathol 2009; 175: 2159-70.
19. Hashizume H, Falcon BL, Kuroda T, et al. Complementary actions of inhibitors of angiopoietin-2 and VEGF on tumor angiogenesis and growth. Cancer Res 2010; 70: 2213-23.
20. Lobov IB, Brooks PC, Lang RA,. Angiopoietin-2 displays VEGF-dependent modulation of capillary structure and endothelial cell survival in vivo. Proc Natl Acad Sci USA 2002; 99: 11205-10.